← All trials
NCT00000620
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 1999
- Primary completion
- Jun 1, 2009
- Completion date
- Dec 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 10251
- Arms / groups
- 6 / —
- Source
- AACT · pre-existing
Sponsors
- National Heart, Lung, and Blood Institute (NHLBI)Lead sponsor
- Wake Forest UniversityOverall official - principal investigator
- Columbia UniversityStudy chair
- National Heart, Lung, and Blood Institute (NHLBI)Study director
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator
- National Institute on Aging (NIA)Collaborator
- National Eye Institute (NEI)Collaborator
- Centers for Disease Control and Prevention (CDC)Collaborator
Drugs studied
- simvastatin
- simvastatin
- candesartan
- candesartan
- chlorthalidone
- chlorthalidone
- diltiazem
- diltiazem
- insulin glargine
- insulin glargine
- glimepiride
- glimepiride
- acarbose
- acarbose
- hydralazine
- hydralazine
- insulin detemir
- insulin detemir
- repaglinide
- repaglinide
- valsartan
- valsartan
- sitagliptin
- sitagliptin
- terazosin
- terazosin
- felodipine
- felodipine
- benazepril
- benazepril
- metoprolol
- metoprolol
- fenofibrate
- fenofibrate
- insulin lispro
- insulin lispro
- pioglitazone
- pioglitazone
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.